|1.||Roberts, Charles T: 2 articles (01/2015 - 09/2013)|
|2.||Gravett, Michael G: 2 articles (01/2015 - 09/2013)|
|3.||Nagalla, Srinivasa R: 2 articles (01/2015 - 09/2013)|
|4.||Bean, Eric: 1 article (01/2015)|
|5.||Laurie, Amber: 1 article (01/2015)|
|6.||Rasanen, Juha: 1 article (01/2015)|
|7.||Quinn, Matthew J: 1 article (01/2015)|
|8.||Snyder, Caryn K: 1 article (09/2013)|
|9.||Rasanen, Juha P: 1 article (09/2013)|
|10.||Mihalache, Raluca: 1 article (09/2013)|
12/01/1995 - "The spatial correlation of myofibroblast phenotype, TGF beta and bFGF synthesis and the occurrence of the oncofetal molecular fibronectin variants (ED-B+ and oncofetal glycosylated fibronectin) in the active proliferative fibromatosis nodules suggests a pathogentic role of these growth factors and matrix components in the tumorous tissue formation process. "
11/01/1995 - "Differential expression of fibronectin splice variants, oncofetal glycosylated fibronectin and laminin isoforms in nodular palmar fibromatosis."
11/01/1995 - "The tissue formation process in nodular palmar fibromatosis (Morbus Dupuytren) was investigated by the demonstration of fibronectin splice variants (ED-A and ED-B fibronectin), de novo glycosylated fibronectin and laminin isoforms (A, M, B1, B2, s chains) in association to the proliferative activity (Ki-67 antigen) and the occurrence of myofibroblast phenotype (alpha-smooth muscle actin, desmin). "
12/01/1995 - "To investigate a possible implication of these growth factors in the tissue formation process of palmar fibromatosis, TGF beta 1/2 and bFGF synthesis, as well as TGF beta 1/3 and bFGF tissue distribution, is demonstrated by RNA in situ hybridization and/or immunohistochemistry in relation to myofibroblast phenotype development (alpha-smooth muscle actin, desmin immunohistochemistry), expression of different fibronectin isoforms (ED-A+, ED-B+ and oncofetal glycosylated fibronectin immunohistochemistry, fibronectin RNA in situ hybridization) and cellular activity (cyclin RNA in situ hybridization, Ki-67 immunolabelling). "
10/01/2008 - "IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC)."
12/01/1996 - "Initial results suggest a correlation between the amount of ED-B+ and de novo-glycosylated fibronectin in tumour stroma and the behaviour of carcinomas with regard to their invasiveness and propensity for metastatic dissemination. "
|3.||Gestational Diabetes (Gestational Diabetes Mellitus)
|2.||Protein Isoforms (Isoforms)
|4.||Transforming Growth Factor beta1 (TGF beta 1)
|5.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|7.||Transforming Growth Factor beta (TGF-beta)
|8.||RNA (Ribonucleic Acid)